- Home
- DBVT vs HSPO Comparison
DBVT vs HSPO Comparison
Compare DBVT & HSPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- HSPO
- Stock Information
- Founded
- DBVT 2002
- HSPO 2014
- Country
- DBVT France
- HSPO United States
- Employees
- DBVT N/A
- HSPO N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- HSPO Blank Checks
- Sector
- DBVT Health Care
- HSPO Finance
- Exchange
- DBVT Nasdaq
- HSPO Nasdaq
- Market Cap
- DBVT 102.0M
- HSPO 92.0M
- IPO Year
- DBVT N/A
- HSPO 2022
- Fundamental
- Price
- DBVT $6.46
- HSPO $11.89
- Analyst Decision
- DBVT Strong Buy
- HSPO
- Analyst Count
- DBVT 2
- HSPO 0
- Target Price
- DBVT $22.50
- HSPO N/A
- AVG Volume (30 Days)
- DBVT 1.1M
- HSPO 3.2K
- Earning Date
- DBVT 05-06-2025
- HSPO 01-01-0001
- Dividend Yield
- DBVT N/A
- HSPO N/A
- EPS Growth
- DBVT N/A
- HSPO 2.63
- EPS
- DBVT N/A
- HSPO 0.91
- Revenue
- DBVT $4,200,000.00
- HSPO N/A
- Revenue This Year
- DBVT $1,679.52
- HSPO N/A
- Revenue Next Year
- DBVT $535.67
- HSPO N/A
- P/E Ratio
- DBVT N/A
- HSPO $13.01
- Revenue Growth
- DBVT N/A
- HSPO N/A
- 52 Week Low
- DBVT $0.44
- HSPO $10.87
- 52 Week High
- DBVT $7.28
- HSPO $12.41
- Technical
- Relative Strength Index (RSI)
- DBVT 65.77
- HSPO 69.57
- Support Level
- DBVT $3.91
- HSPO $11.61
- Resistance Level
- DBVT $7.28
- HSPO $11.75
- Average True Range (ATR)
- DBVT 0.60
- HSPO 0.01
- MACD
- DBVT 0.20
- HSPO 0.01
- Stochastic Oscillator
- DBVT 75.67
- HSPO 100.00
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.